Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

K. Shidahara, K. Hayashi, K. E. Sada, S. Hiramatsu, M. Morishita, H. Watanabe, Y. Matsumoto, T. Kawabata, J. Wada

Research output: Contribution to journalArticle

Abstract

We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

Original languageEnglish
Pages (from-to)1374-1377
Number of pages4
JournalLupus
Volume27
Issue number8
DOIs
Publication statusPublished - Jul 1 2018

Keywords

  • Anti-aquaporin-4 antibody
  • neuromyelitis optica
  • rituximab
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab'. Together they form a unique fingerprint.

  • Cite this

    Shidahara, K., Hayashi, K., Sada, K. E., Hiramatsu, S., Morishita, M., Watanabe, H., Matsumoto, Y., Kawabata, T., & Wada, J. (2018). Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab. Lupus, 27(8), 1374-1377. https://doi.org/10.1177/0961203318760994